Future Directions In Prostate Cancer Diagnosis
J. Klink, E. Klein
Published 2013 · Medicine
Download PDFAnalyze on Scholarcy
Since Hugh Hampton Young described his series of 111 prostate cancer patients in 1909 (Young, Ann Surg 50(6):1144–233, 1909), much progress has been made in the diagnosis of prostate cancer. Many of Dr. Young’s patients were diagnosed when symptoms of advanced prostate cancer developed, and many died of their disease. A century later, 80 % of prostate cancers are diagnosed while still localized (Siegel et al. CA Cancer J Clin 61(4):212–36, 2011). The prostate cancer mortality rate now stands at its lowest point in more than 70 years after falling for 14 consecutive years despite the aging of the population (Siegel et al. CA Cancer J Clin 61(4):212–36, 2011). While many factors have contributed to these trends, earlier diagnosis has played a large role in improving outcomes.
This paper references
American Cancer Society Guideline for the Early Detection of Prostate Cancer: Update 2010
A. M. Wolf (2010)
A common variant associated with prostate cancer in European and African populations
Laufey T Amundadottir (2006)
XV. Cancer of the Prostate: A Clinical, Pathological and Post-Operative Analysis of 111 Cases.
H. H. Young (1909)
Current status of MRI for the diagnosis, staging and prognosis of prostate cancer: implications for focal therapy and active surveillance
A. Villers (2009)
Multiple loci identified in a genome-wide association study of prostate cancer
G. Thomas (2008)
Multiple newly identified loci associated with prostate cancer susceptibility
R. Eeles (2008)
Molecular Detection of Localized Prostate Cancer Using Quantitative Methylation-Specific PCR on Urinary Cells Obtained Following Prostate Massage
M. Rouprêt (2007)
Hypermethylation of GSTP1, CD44, and E-cadherin genes in prostate cancer among US Blacks and Whites.
K. Woodson (2003)
Patient Decision Aids for Prostate Cancer Treatment: A Systematic Review of the Literature
G. Lin (2009)
Isolation of rare circulating tumour cells in cancer patients by microchip technology
S. Nagrath (2007)
Glucuronide formation in patients with constitutional hepatic dysfunction (Gilbert's disease).
R. Schmid (1959)
Epigenetics: A Landscape Takes Shape
A. Goldberg (2007)
DNA methylomes, histone codes and miRNAs: tying it all together.
Sonia Guil (2009)
A risk prediction algorithm based on family history and common genetic variants: application to prostate cancer with potential clinical impact
R. Macinnis (2011)
Two Independent Prostate Cancer Risk–Associated Loci at 11q13
S. Zheng (2009)
Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP.
D. Duggan (2007)
A novel prostate cancer susceptibility locus at 19q13.
F. Hsu (2009)
A miRNA expression signature that separates between normal and malignant prostate tissues
Jessica Carlsson (2011)
Global histone modification patterns predict risk of prostate cancer recurrence
D. Seligson (2005)
Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes
J. Gudmundsson (2007)
The history of cancer epigenetics
A. Feinberg (2004)
Genetics of prostate cancer risk.
M. Pomerantz (2010)
Disease-free survival difference between African Americans and whites after radical prostatectomy for local prostate cancer: a multivariable analysis.
I. Powell (2002)
Genome-wide association study identifies new prostate cancer susceptibility loci.
F. Schumacher (2011)
Screening and prostate-cancer mortality in a randomized European study.
F. Schroeder (2009)
Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility
J. Gudmundsson (2009)
Systematic confirmation study of reported prostate cancer risk‐associated single nucleotide polymorphisms in Chinese men
F. Liu (2011)
Race, biochemical disease recurrence, and prostate–specific antigen doubling time after radical prostatectomy
R. Hamilton (2007)
Genome-wide association study identifies five new susceptibility loci for prostate cancer in the Japanese population
R. Takata (2010)
Mortality results from a randomized prostate-cancer screening trial.
G. Andriole (2009)
American Cancer Society Guidelines for the Early Detection of Cancer, 2006
R. Smith (2006)
Inherited genetic variant predisposes to aggressive but not indolent prostate cancer
J. Xu (2010)
CpG island hypermethylation in cell-free serum DNA identifies patients with localized prostate cancer.
J. Ellinger (2008)
MicroRNA in prostate, bladder, and kidney cancer: a systematic review.
J. Catto (2011)
American Cancer Society Guidelines for the Early Detection of Cancer
R. Smith (2002)
Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects.
M. Hoque (2005)
Sequence variants at 22q13 are associated with prostate cancer risk.
Jielin Sun (2009)
Ethnic group‐related differences in CpG hypermethylation of the GSTP1 gene promoter among African‐American, Caucasian and Asian patients with prostate cancer
H. Enokida (2005)
Circulating microRNAs as stable blood-based markers for cancer detection
P. S. Mitchell (2008)
Epigenetics in cancer.
M. Esteller (2008)
The role of perineural space invasion in the local spread of prostatic adenocarcinoma.
A. Villers (1989)
MicroRNA expression profiles classify human cancers
J. Lu (2005)
Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study
Z. Kote-Jarai (2011)
Proteins that bind methylated DNA and human cancer: reading the wrong words
L. Lopez-Serra (2008)
Radical prostatectomy versus watchful waiting in early prostate cancer.
A. Bill-Axelson (2005)
Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study
A. Vickers (2010)
Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer
J. Gudmundsson (2008)
Outcomes of localized prostate cancer following conservative management.
G. Lu-Yao (2009)
Isolation and Characterization of Circulating Tumor Cells from Patients with Localized and Metastatic Prostate Cancer
S. Stott (2010)
Identification of a new prostate cancer susceptibility locus on chromosome 8q24
M. Yeager (2009)
Chromatin Modifications and Their Function
T. Kouzarides (2007)
Dynamic contrast-enhanced-magnetic resonance imaging evaluation of intraprostatic prostate cancer: correlation with radical prostatectomy specimens.
P. Puech (2009)
Progress in cancer screening practices in the United States
J. Swan (2003)
Multiple loci on 8q24 associated with prostate cancer susceptibility
Ali Amin Al Olama (2009)
Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer
J. D. de Bono (2008)
Cancer statistics, 2011
R. Siegel (2011)
Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24
J. Gudmundsson (2007)
Evidence for two independent prostate cancer risk–associated loci in the HNF1B gene at 17q12
Jielin Sun (2008)
Heterogeneous gene methylation patterns among pre-invasive and cancerous lesions of the prostate: a histopathologic study of whole mount prostate specimens.
K. Woodson (2004)
Inherited susceptibility to common cancers.
W. Foulkes (2008)
Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate.
T. Stamey (1987)
Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program.
M. Hayat (2007)
American Cancer Society Guidelines for the Early Detection of Cancer: Update of Early Detection Guidelines for Prostate, Colorectal, and Endometrial Cancers: ALSO: Update 2001—Testing for Early Lung Cancer Detection
R. Smith (2001)
Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma
Annika Schäfer (2010)
Identification of seven new prostate cancer susceptibility loci through a genome-wide association study
R. Eeles (2009)
Genome-wide association study of prostate cancer identifies a second risk locus at 8q24
M. Yeager (2007)
Prostate specific antigen best practice statement: 2009 update.
K. Greene (2009)
Global levels of histone modifications predict prostate cancer recurrence.
J. Ellinger (2010)
MicroRNA expression profiling in prostate cancer.
K. Porkka (2007)
Epigenetics in prostate cancer: biologic and clinical relevance.
C. Jerónimo (2011)
This paper is referenced by
A Meta-Analysis Identifies New Loci Associated with Body Mass index in Individuals of African Ancestry
K. Monda (2013)